Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 5/20 | 0.51 |
| ▸ | MERTK | Q12866 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625612 | 0.93 | VCAM1 (0.51) | VCAM1MERTKTSHRMAPK1MAPT | |
| SCHEMBL1344102 | 0.86 | VCAM1 (0.56) | VCAM1MERTKTSHRMAPK1MAPT | |
| SCHEMBL7642508 | 0.85 | VCAM1 (0.58) | VCAM1MERTKTSHRMAPK1MAPT | |
| SCHEMBL773066 | 0.85 | VCAM1 (0.49) | VCAM1TSHRMAPTGRIA1GRIA2 | |
| SCHEMBL9536669 | 0.84 | VCAM1 (0.56) | VCAM1MERTKTSHRMAPK1MAPT | |
| SCHEMBL1343713 | 0.84 | VCAM1 (0.61) | VCAM1MERTKTSHRMAPK1MAPT | |
| SCHEMBL7024321 | 0.84 | VCAM1 (0.47) | VCAM1TSHRMAPTGRIA1GRIA2 | |
| SCHEMBL14739198 | 0.80 | VCAM1 (0.47) | VCAM1TSHRMAPTGRIA1GRIA2 | |
| SCHEMBL1624405 | 0.80 | VCAM1 (0.56) | VCAM1MERTKTSHRMAPK1MAPT | |
| SCHEMBL1344104 | 0.79 | VCAM1 (0.51) | VCAM1MERTKTSHRMAPTGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146044-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | INCRELAND (CN) | 2026-05-28 | — | — | US | disclosed |
| EP-4745142-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Increland (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025061203-A1 | IRAK DEGRADATION AGENT AND USE THEREOF | 成都茵创园医药科技有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025011655-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 成都茵创园医药科技有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| EP-4271664-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-2217596-B1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
| EP-2217596-A2 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | Schering Corporation (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009055331-A2 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| US-5968958-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS OR ENZYME INHIBITORS | MERCK FROSST CANADA, INC. (CA) | 1999-10-19 | — | — | US | disclosed |
| WO-1996023786-A1 | 5-METHANESULFONAMIDO-3H-ISOBENZOFURAN-1-ONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 1996-08-08 | — | — | WO | disclosed |
| EP-0273369-B1 | NEW ALKANESULFONANILIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-04 | — | — | EP | disclosed |
| US-4866091-A | ANTINFLAMMATORY AGENTS, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-12 | — | — | US | disclosed |
| CN-87108295-A | New alkane sulfonyl aniline derivative and its medicinal compositions and preparation method | — | 1988-07-13 | — | — | CN | disclosed |
| EP-0273369-A2 | New alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | VCAM1 3876/4885MERTK 1044/4885TSHR 629/4885 |
| US-20260146044-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | IRAK4, IRAK2, IRAK1 | VCAM1 1737/4885MERTK 1386/4885TSHR 3793/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | VCAM1 3606/4885MERTK 497/4885TSHR 3319/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | VCAM1 3606/4885MERTK 497/4885TSHR 3319/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | VCAM1 4298/4885MERTK 2201/4885TSHR 334/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | VCAM1 3606/4885MERTK 497/4885TSHR 3319/4885 |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | VCAM1 1347/4885MERTK 1567/4885TSHR 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.